Showing results (131-140 of 158) with videos related to

Sort By:
Pageof 16
Hepatology (Baltimore, Md.)|September 21, 2023
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosisMary E Rinella, Hsiao D Lieu, Kris V Kowdley, et al.
Diabetes Care|May 28, 2025
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes AssociationKenneth Cusi, Manal F Abdelmalek, Caroline M Apovian, et al.
Hepatology (Baltimore, Md.)|April 18, 2019
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab TrialsArun J Sanyal, Stephen A Harrison, Vlad Ratziu, et al.
Hepatology (Baltimore, Md.)|October 18, 2021
Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitisArun J Sanyal, Quentin M Anstee, Michael Trauner, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 23, 2023
Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b StudyManal F Abdelmalek, Arun J Sanyal, Atsushi Nakajima, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|October 31, 2019
Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity ParadoxSanjaya K Satapathy, Yu Jiang, Uchenna Agbim, et al.
Hepatology (Baltimore, Md.)|August 1, 2021
A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH CirrhosisJaime Bosch, Chuhan Chung, Oscar M Carrasco-Zevallos, et al.
Hepatology (Baltimore, Md.)|August 24, 2017
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosisScott L Friedman, Vlad Ratziu, Stephen A Harrison, et al.
Gastroenterology|July 11, 2018
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic SteatohepatitisStephen A Harrison, Manal F Abdelmalek, Stephen Caldwell, et al.
Journal of Hepatology|October 7, 2018
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertibSaumya Jayakumar, Michael S Middleton, Eric J Lawitz, et al.
Pageof 16